Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 7, 2021.
Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Elyse Stock, MD, and Thomas Shoivitz, MD, on the recently launched phase 2/3 trial of Biohaven's investigational oral migraine treatment, zavegepant.
This segment of the NeurologyLive Peer Exchange, "Management of Progressive Multiple Sclerosis," features Bruce Cree, MD, PhD; Joseph R. Berger, MD; Kristen Krysko, MD; Fred D. Lublin, MD; and Robert Fox, MD, offering their outlook on the management of patients with multiple sclerosis in the coming years.
The neurologist from Cleveland Clinic discussed his study presented at the 2021 American Academy of Neurology Annual Meeting involving the use of responsive neurostimulation in older adults with drug-resistant focal epilepsy and further expanding research in this space.
The associate professor of neurology at Columbia University spoke to the impact that the ice bucket challenge and the ALS Awareness Month have had on funding and advances in the ALS treatment landscape.
In this segment of the NeurologyLive Peer Exchange, "The Migraine Patient Journey: Episodic Migraine and CGRP Inhibitors," a patient advocate, Jill Dehlin, RN, explains why patients with migraine should connect with other patients via patient support programs and take a proactive role in managing their condition.